Suven Life Sciences Ltd (Suven) announced in a filing to NSE today that the grant of one product patent from Canada (2878217) and one product patent from Hong Kong (HK1176619) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders which are associated with Neurodegenerative diseases. These Patents are valid through 2032 and 2030 respectively. These granted claims of the patents include the class of selective 5-HT compounds which are discovered by Suven and are being d